Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations
Life · 08.08.2026 · 16 (8) · 1301
DOI: 10.3390/life16081301 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life, online erschienen am 08.08.2026. Verfasst von Jawaria und 5 weiteren Autor:innen. Beteiligte Einrichtung: Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering-C (NIBGE), Faisalabad 38000, Pakistan. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development, and Innovation Fund of Hungary.
Abstract (Originalsprache)
Hypertension remains a major global health burden, and control rates remain suboptimal because of poor medication adherence and limitations of existing therapies, including escape within the renin–angiotensin–aldosterone system. Zilebesiran, a first-in-class, subcutaneously administered small interfering RNA therapeutic, represents a promising advance in hypertension management. Through N-acetylgalactosamine-mediated hepatic delivery, zilebesiran selectively silences angiotensinogen (AGT) messenger RNA, the transcript encoding the common precursor of all angiotensin peptides. This upstream intervention reduces AGT production and produces durable blood pressure lowering that can persist for up to 6 months after a single dose. This review summarizes the mechanism of action of zilebesiran, its pharmacokinetic and pharmacodynamic properties, and the available phase 1 and phase 2 clinical evidence, including the KARDIA program. We also place zilebesiran within the evolving antihypertensive landscape by comparing it with aldosterone synthase inhibitors, dual endothelin receptor antagonists, and brain aminopeptidase A inhibitors. Finally, we discuss translational challenges, including reversal strategies for emergency situations, monitoring considerations, and potential roles for personalized dosing. Early-phase and phase 2 trials show dose-dependent and durable reductions in serum AGT and blood pressure with infrequent dosing; however, long-term safety, cardiovascular outcome benefit, and generalizability in diverse high-risk populations remain to be established, and zilebesiran remains investigational while phase 3 outcome testing is underway.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering-C (NIBGE), Faisalabad 38000, Pakistan.
- Pakistan Institute of Engineering and Applied Sciences (PIEAS), Islamabad 45650, Pakistan.
- Department of Bioinformatics and Biotechnology, Government College University Faisalabad, Faisalabad 38000, Pakistan.
- Department of Biochemistry, Government College University Faisalabad, Faisalabad 38000, Pakistan.
- Heart and Vascular Center, Semmelweis University, 1122 Budapest, Hungary.
ORCID-Profile: Jawaria, Yusra Zarlashat, Muhammad Ebad Asif Khan, Enrique Mandado Loureiro, Edit Dósa
Förderung
- National Research, Development, and Innovation Fund of Hungary
Zitieren
APA
Jawaria, Noor, A., Zarlashat, Y., Khan, M. E. A., Loureiro, E. M., & Dósa, E. (2026). Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations. Life, 16(8), 1301. https://doi.org/10.3390/life16081301
Vancouver
Jawaria, Noor A, Zarlashat Y, Khan MEA, Loureiro EM, Dósa E. Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations. Life. 2026;16(8):1301. doi:10.3390/life16081301
BibTeX
@article{Jawaria2026,
author = {Jawaria and Noor, Areeba and Zarlashat, Yusra and Khan, Muhammad Ebad Asif and Loureiro, Enrique Mandado and Dósa, Edit},
title = {Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations},
journal = {Life},
year = {2026},
volume = {16},
number = {8},
pages = {1301},
doi = {10.3390/life16081301}
}
EUVIMED